Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance.
about
Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directionsAntimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial.Second-line rescue therapy of helicobacter pylori infection.Aqueous and organic solvent-extracts of selected south African medicinal plants possess antimicrobial activity against drug-resistant strains of Helicobacter pylori: inhibitory and bactericidal potentialEfficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy.Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.The incidence of primary antibiotic resistance of Helicobacter pylori in VietnamAntibiotics resistance rate of Helicobacter pylori in Bhutan"Rescue" regimens after Helicobacter pylori treatment failure.Current recommendations for Helicobacter pylori therapies in a world of evolving resistance.The sequential therapy regimen for Helicobacter pylori eradication.A clinician's guide to salvage therapy for persistent Helicobacter pylori infection.Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials.Overview of the phytomedicine approaches against Helicobacter pylori.Emerging therapies for the treatment of Helicobacter pylori infections.Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis.A prospective evaluation of levofloxacin-based triple therapy for refractory Helicobacter pylori infection in Australia.Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy.Antibiotic susceptibility of Helicobacter pylori in Iceland.ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.MOLECULAR DETECTION OF CLARITHROMYCIN AND FLUOROQUINOLONES RESISTANCE IN HELICOBACTER PYLORI INFECTION, DIRECTLY APPLIED TO GASTRIC BIOPSIES, IN AN URBAN BRAZILIAN POPULATION.Comparison of levofloxacin versus clarithromycin efficacy in the eradication of Helicobacter pylori infection.Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation.Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan.Eradication of H. pylori Infection: the Challenge is on if Standard Therapy FailsCiprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial.Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.First- and second-line Helicobacter pylori eradication with modified sequential therapy and modified levofloxacin-amoxicillin-based triple therapy.Should quinolones come first in Helicobacter pylori therapy?Rescue Therapy for Helicobacter pylori Infection 2012.Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany.High primary antibiotic resistance of Helicobacter Pylori strains isolated from dyspeptic patients: A prevalence cross-sectional study in Spain.
P2860
Q26778023-04832985-1D73-4EF8-8544-9FD8BCDA17A4Q33843119-9C073A3B-A6B1-4E65-8441-AD3E0A658A4DQ34409114-D2D8F1C8-C6CD-4D73-AF29-A3A97988FE05Q35296965-E9A5B18B-233C-4344-9425-BBEB74975699Q35806155-923465B3-DA6E-41F2-BCFA-5CA6DA015E6FQ35810200-B0C3AA9C-BF43-4A55-9BC8-378B0A1EC1F4Q35841617-ED52EC59-AECB-4AE4-BCA6-F912C6448FDBQ36357419-59CAEDBD-91EE-42E4-9C4E-DC76A31E311CQ36565896-BF3DD1D7-28E9-46EC-BD79-9E75C47BD90BQ37142225-932E1CBF-AAF6-4A8D-B0E4-7F3DD51A542DQ37273653-62C42269-F696-4000-B602-E7553644F2EDQ37591509-A6F5F912-43A2-4FD1-AA07-299D17FA04DFQ37703245-BF00581E-3440-4374-9DC4-C5095AAC4028Q37858374-E21AA62E-A601-4773-B75A-76FFE1A81FEAQ37899929-2D11DBB0-AFF8-41AE-B4DA-EDDBBA97868AQ38093864-51A3E617-2BB5-4F69-9802-EE58DAC8D65BQ38182087-EAE878F6-AA43-4E39-B92C-8CD5B5C4FE8CQ38219017-963F8325-975F-49DF-A508-A4A01E449469Q38424698-AF3C36A4-56EB-472B-84CF-E75A37F8FA78Q38865607-022603DA-52D7-4B99-B25E-ABB33E2011EBQ38874731-D80BC845-140D-4BC9-9957-38507DD1FF30Q39014376-879EDCC6-C6FC-4736-9696-0A20C20E54F3Q39496596-100DEC89-C537-49BB-9FF7-7FA84707EF21Q39588933-4CCAE8C2-246D-47A6-8491-0ECF09859AC1Q40238873-92815921-B3BC-4F7A-A963-ADC27D8DE582Q40378087-DD71A236-140B-4C04-A3EA-5982FA54FD46Q40382489-DFA01C96-F02A-44A4-9F46-8316B45B4A03Q40401286-F338AC45-0247-4B4A-9CC8-F16366DC6BF3Q40892650-7609A75B-2F21-45F6-9A67-C0E308BEE933Q40957363-786B789E-E836-40F0-9CE4-695A85DAFC43Q41172569-D04491E0-9C63-4CB8-AD6A-D3BBDECA1B91Q41461677-4252B74C-77E3-425F-8147-EAB642ACFFFDQ41471323-48F1A5AC-9F8D-42E7-A391-23721C19A413Q41694687-58BF025C-D39A-489B-B703-1653E7B311C9Q41807465-8382352C-793B-4DD7-A0B5-1206D0849E23Q42129420-89DE56B4-959B-4BDD-ADC9-6FECA8D5B712Q44482747-D6BA70C1-90F0-427B-99CB-6EED02907678Q44503073-519CC984-B056-4EEC-99D4-79F0654ED25CQ44790817-5C98D3F6-665A-44C0-AF6B-C21A8B406577Q47638155-D271A52D-7C9D-482A-AEF0-054E1A863934
P2860
Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Levofloxacin-based triple ther ...... role of bacterial resistance.
@ast
Levofloxacin-based triple ther ...... role of bacterial resistance.
@en
Levofloxacin-based triple ther ...... role of bacterial resistance.
@nl
type
label
Levofloxacin-based triple ther ...... role of bacterial resistance.
@ast
Levofloxacin-based triple ther ...... role of bacterial resistance.
@en
Levofloxacin-based triple ther ...... role of bacterial resistance.
@nl
prefLabel
Levofloxacin-based triple ther ...... role of bacterial resistance.
@ast
Levofloxacin-based triple ther ...... role of bacterial resistance.
@en
Levofloxacin-based triple ther ...... role of bacterial resistance.
@nl
P2093
P1476
Levofloxacin-based triple ther ...... role of bacterial resistance.
@en
P2093
P304
P356
10.1016/J.DLD.2007.06.016
P50
P577
2007-09-21T00:00:00Z